New York, March 05, 2018:
Leukemia Therapeutics Market Forecast 2018 to 2022
The Global Leukemia Therapeutic Market is expected to exceed more than US$ 12.00 Billion by 2022 at a CAGR of 4% in the given forecast period.
The scope of the report includes a detailed study of global and regional markets on Global Leukemia Therapeutic Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include F. Hoffmann-La Roche Ltd., Amgen, Bristol-Myers Squibb, Novartis International AG., Pfizer, Teva Pharmaceuticals, GlaxoSmithKline plc. Genzyme Corporation, AbbVie Inc. and ARIAD Pharmaceuticals, Inc. among others. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
You Can Browse Full Report: https://www.marketresearchengine.com/leukemia-therapeutics-market
The Global Leukemia Therapeutic Market has been segmented as below:
By Therapy Analysis:
- Biological Therapy
- Radiation therapy
- Targeted therapy
By Type Analysis:
- Chronic leukemia
- Chronic lymphatic leukemia
- Chronic myeloid leukemia
- Acute leukemia
- Acute lymphatic leukemia
- Acute myeloid leukemia
By Regional Analysis:
- North America
- Rest of the World
This report provides:
1) An overview of the global market for Global Leukemia Therapeutic Market and related technologies.
2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2022.
3) Identifications of new market opportunities and targeted promotional plans for Global Leukemia Therapeutic Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
Request Sample Report: https://www.marketresearchengine.com/leukemia-therapeutics-market
Table of Contents
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
4 LEUKEMIA MARKET DYNAMICS
4.1 MARKET OVERVIEW
4.2 BURNING ISSUES
4.3 WINNING IMPERATIVES
4.3.1 BMS STRATEGY ON PRODUCT EDUCATION THROUGH ONLINE SERVICES
4.4 MARKET DYNAMICS
4.4.1 MARKET DRIVERS
184.108.40.206 Innovative therapies to drive the market for leukemia
220.127.116.11 Oncology is the largest therapeutic market with high unmet needs
18.104.22.168 Off-label prescribing drives market growth.
4.4.2 MARKET RESTRAINTS
22.214.171.124 Adverse events of treatment
126.96.36.199 Low production capability for efficient drugs
4.4.3 MARKET OPPORTUNITIES
188.8.131.52 Limited players in the market
184.108.40.206 Growing older male population
220.127.116.11 Leukemia’s underserved patient populations offer potential for market growth
5 LEUKEMIA PRODUCT MARKET
6 LEUKEMIA DRUG PIPELINE (PHASE III)
7 GEOGRAPHIC ANALYSIS
8 COMPETITIVE LANDSCAPE
9 COMPANY PROFILES
9.1 AMBIT BIOSCIENCES CORPORATION
9.2 ARIAD PHARMACEUTICALS INC
9.3 BIOGEN IDEC INC.
9.4 BRISTOL-MYERS SQUIBB
9.5 CELGENE CORPORATION
9.6 CEPHALON INC
9.7 CLAVIS PHARMA ASA
9.8 EISAI CO. LTD.
9.9 ERYTECH PHARMA
9.10 GENMAB A/S
9.11 GENZYME CORPORATION
9.12 GLAXOSMITHKLINE PLC
9.13 NOVARTIS INTERNATIONAL AG
9.14 PFIZER INC
9.15 ROCHE HOLDING AG
9.16 SUNESIS PHARMACEUTICALS INC
9.17 TALON THERAPEUTICS INC
Company Name: Market Research Engine
Contact Person: John Bay
Country: United States